TherapeuticsMD (TXMD) Retained Earnings (2010 - 2026)
TherapeuticsMD (TXMD) posted Retained Earnings of -$952.3 million for Q1 2026, little changed on a QoQ basis from -$952.4 million in Q4 2025, and little changed year-over-year from -$952.1 million in Q1 2025.
TherapeuticsMD (TXMD) Retained Earnings (2010 - 2026) Analysis & Trends
TherapeuticsMD's Retained Earnings history runs 17 years deep, the most recent figure standing at -$952.3 million for Q1 2026.
- Quarterly Retained Earnings changed 0.02% year-over-year to -$952.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$952.3 million (changed 0.02% YoY) and the FY2025 annual result came in at -$952.4 million, changed 0.06% from the prior year.
- Retained Earnings was -$952.3 million for Q1 2026 at TherapeuticsMD, roughly flat from -$952.4 million in the prior quarter.
- Across five years, Retained Earnings topped out at $979.2 million in Q3 2024 and bottomed at -$1.1 billion in Q1 2022.
- A 5-year average of -$737.5 million and a median of -$951.8 million in 2025 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2024 — Retained Earnings surged 203.82% — and 2025, when it plunged 197.29%.
- TherapeuticsMD's Retained Earnings stood at -$939.4 million in 2022, then slipped by 1.09% to -$949.6 million in 2023, then dropped by 0.23% to -$951.8 million in 2024, then dropped by 0.06% to -$952.4 million in 2025, then rose by 0.01% to -$952.3 million in 2026.
- Business Quant data shows TXMD's Retained Earnings at -$952.3 million in Q1 2026, -$952.4 million in Q4 2025, and -$951.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 8.83 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -1.81 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -2.13 Bn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - | -952.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -952.30 Mn |
| Dec 31, 2025 | -952.39 Mn |
| Sep 30, 2025 | -951.77 Mn |
| Jun 30, 2025 | -951.92 Mn |
| Mar 31, 2025 | -952.48 Mn |
| Dec 31, 2024 | -951.82 Mn |
| Sep 30, 2024 | 979.16 Mn |
| Jun 30, 2024 | -951.47 Mn |
| Mar 31, 2024 | 979.03 Mn |
| Dec 31, 2023 | -949.64 Mn |
| Sep 30, 2023 | -948.76 Mn |
| Jun 30, 2023 | -945.38 Mn |
| Mar 31, 2023 | -942.97 Mn |
| Dec 31, 2022 | -939.36 Mn |
| Sep 30, 2022 | -1.02 Bn |
| Jun 30, 2022 | -988.10 Mn |
| Mar 31, 2022 | -1.10 Bn |
| Dec 31, 2021 | -1.05 Bn |
| Sep 30, 2021 | -1.01 Bn |
| Jun 30, 2021 | -960.98 Mn |